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AbsTrACT
Objective To assess the effectiveness and safety of 
antibiotic regimens used to treat pelvic inflammatory 
disease (PID).
Design This is a systematic review and meta-analysis 
of randomised controlled trials (RCTs). Risk of bias was 
assessed using the criteria outlined in the Cochrane 
guidelines. Quality of evidence was assessed using the 
Grading of Recommendations Assessment, Development 
and Evaluation.
Data sources Eight electronic databases were 
searched from date of inception up to July 2016. 
Database searches were complemented by screening 
of reference lists of relevant studies, trial registers, 
conference proceeding abstracts and grey literature.
Eligibility criteria RCTs comparing the use of 
antibiotics with placebo or other antibiotics for the 
treatment of PID in women of reproductive age, either as 
inpatient or outpatient treatment.
results We included 37 RCTs (6348 women). The 
quality of evidence ranged from very low to high, the 
main limitations being serious risk of bias (due to poor 
reporting of study methods and lack of blinding), serious 
inconsistency and serious imprecision. There was no 
clear evidence of a difference in the rates of cure for 
mild-moderate or for severe PID for the comparisons 
of azithromycin versus doxycycline, quinolone versus 
cephalosporin, nitroimidazole versus no use of 
nitroimidazole, clindamycin plus aminoglycoside versus 
quinolone, or clindamycin plus aminoglycoside versus 
cephalosporin. No clear evidence of a difference between 
regimens in antibiotic-related adverse events leading to 
discontinuation of therapy was observed.
Conclusions We found no conclusive evidence that 
one regimen of antibiotics was safer or more effective 
than any other for the treatment of PID, and there 
was no clear evidence for the use of nitroimidazoles 
(metronidazole) compared with the use of other drugs 
with activity against anaerobes. More evidence is needed 
to assess treatments for women with PID, particularly 
comparing regimens with or without the addition 
of nitroimidazoles and the efficacy of azithromycin 
compared with doxycycline.
InTrODuCTIOn
Pelvic inflammatory disease (PID) in women is 
described as an inflammation of the upper genital 
tract and surrounding structures as a result of 
ascending infection from the lower genital tract—
bacteria spread directly from the cervix to the 
endometrium and on to the upper genital tract.1 
The signs and symptoms of PID are not specific 
and may range from asymptomatic to abdominal 
pain/tenderness, fever, vomiting, dyspareunia and 
menorrhagia.2
The incidence of PID in the UK has been esti-
mated to range between 1.1% and 1.7% among 
women between 16 and 46 years old.3 4 Among 
women with PID, 10%–20% may become infer-
tile, 40% will develop chronic pelvic pain, and 
10% of those who conceive will have an ectopic 
pregnancy.5–8 The cost of pelvic infection has been 
estimated to exceed US$2.4 billion in the USA, 
and the mean total cost per episode managed as an 
outpatient is around US$700.9 In the UK, the mean 
cost of an uncomplicated episode of PID is £163, 
considering an average of two outpatient appoint-
ments per woman across all settings.10
PID requires effective treatment to reduce the inci-
dence of chronic pelvic pain, infertility and ectopic 
pregnancy. The main intervention for treating acute 
PID is the use of broad-spectrum antibiotics which 
cover Chlamydia trachomatis, Neisseria gonorrhoeae 
and anaerobic bacteria, but the optimal treatment 
strategy is unclear. A variety of antibiotic regimens 
and routes of administration (intravenous, intramus-
cular or oral) have been used, with marked geograph-
ical variation. Current practice generally involves the 
use of multiple agents to provide broad antimicrobial 
cover, but the best combination of agents is unknown. 
Guidelines have been produced in the USA,2 and in 
Europe,11 to guide therapy, but these have not been 
based on a systematic review. The authors of the 
current Centers for Disease Control and Prevention 
(CDC) and International Union against Sexually 
Transmitted Infections (IUSTI) guidelines state that 
there is limited evidence for the need to eradicate 
anaerobes or for the use of alternative regimens, such 
as azithromycin.2 11
The current review is an abridged version of 
a Cochrane systematic review and presents the 
main findings from the primary outcomes and 
an enhanced discussion section.12 This review 
addresses clinical questions raised in the current 
guidelines on the treatment of PID2 11 regarding the 
effectiveness and safety of nitroimidazole, the rela-
tive benefits of azithromycin versus doxycycline, 
the use of quinolones, and the relative benefits of 
cephalosporins compared with clindamycin plus 
aminoglycoside, to inform future guideline devel-
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METhODs
We used Cochrane methodology,13 following our published 
protocol.14
Methods for identification of studies
We searched the Cochrane Sexually Transmitted Infections 
Review Group’s Specialised Register, the Cochrane Central 
Register of Controlled Trials, MEDLINE, MEDLINE In-Pro-
cess & Other Non-Indexed Citations, MEDLINE Daily Update, 
Embase, LILACS and Web of Science up to July 2016. The 
complete search strategy is available in the Cochrane review.12 
We screened the reference lists of all identified randomised 
controlled trials (RCTs) and previous systematic reviews on 
similar topics for additional relevant articles. Furthermore, we 
searched trial registers, conference proceeding abstracts and grey 
literature. We contacted the authors of all RCTs identified by 
other methods, as well as pharmaceutical companies producing 
‘antibiotic therapy’ for ‘pelvic inflammatory disease (PID)’.
Types of studies
We included RCTs, including those which did not describe their 
method of randomisation (ie, where the authors stated that treat-
ment was randomised without providing further details). Trials 
were included irrespective of publication status, publication year 
or language. We excluded quasi-randomised trials because they 
produce effects estimates indicating more extreme benefits when 
compared with RCTs.13 We also excluded cross-over and cluster 
trials.
selection of studies
Two review authors (DGF and RVD) performed an initial screen 
of titles and abstracts retrieved by the search, and we retrieved 
the full text of all potentially eligible studies. Two review 
authors (DGF and RVD) independently examined these studies 
for compliance with the inclusion criteria and selected studies 
that met these criteria. Disagreements regarding eligibility were 
resolved by discussion or by consulting a third review author 
(JR).
Inclusion criteria
RCTs were included in the review if the women participating 
in the trial were of reproductive age (14 years of age or older) 
diagnosed as having acute PID (symptoms for less than 6 weeks) 
based on clinical findings, laparoscopy, endometrial biopsy, or 
detectable N. gonorrhoeae or C. trachomatis in the upper genital 
tract. We limited our review to comparison of drugs in current 
use that are recommended for consideration by the 2015 CDC 
guidelines for treatment of PID.2
Outcomes
The primary outcomes were clinical cure according to the 
criteria defined by the treating physician (eg, resolution or 
improvement of signs and symptoms related to PID) and antibi-
otic-related adverse events leading to discontinuation of therapy. 
For secondary outcomes, please see the full Cochrane systematic 
review.12
Where studies included women with various types of pelvic 
infection, we considered only women with endometritis, salpin-
gitis, parametritis or oophoritis (not related to labour, delivery, 
cancer or surgery). Where studies reported multiple time points, 
we included outcomes at between 14 and 28 days after initiation 
of treatment.
Data extraction
Data from each study were extracted independently by two of 
the three review authors (SF, DGF, RVD) using a data extraction 
form that the review authors designed and pilot-tested. 
Disagreements were resolved by consensus or by consulting a 
fourth review author (JR or RFS). If a study had more than two 
intervention arms, we included or combined only those that met 
the predefined inclusion criteria. Where studies had multiple 
publications, we used the main trial report as the reference and 
derived additional details from secondary papers. We corre-
sponded with study investigators for further data as required.
Quality of evidence
For each included trial, three review authors (SF, DGF, RVD) 
independently assessed the risk of bias using the criteria outlined 
in the Cochrane guidelines.13 Disagreements were resolved by 
discussion or by involving a third review author (JR or RFS).
Two reviewers (SF, RFS) independently assessed and graded 
the evidence according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE).15 Disa-
greements were resolved by discussion or by involving a third 
review author (JR). The GRADE tables are available in the full 
Cochrane review.12
Data synthesis and analysis
Data analyses were performed using Review Manager V.5.3.16 
A fixed-effect meta-analysis was used for combining data 
where it was reasonable to assume that trials were estimating 
the same underlying treatment effect (ie, where trials were 
examining the same intervention, and the trials’ populations 
and methods were sufficiently similar). We conducted separate 
analyses for mild-moderate and severe PID based on the CDC 
criteria.2 If there was clinical heterogeneity sufficient to expect 
that the underlying treatment effects differed between trials, or 
if substantial statistical heterogeneity was detected (I2=40% or 
greater), a random-effects meta-analysis was planned to produce 
an overall summary if a mean treatment effect across trials was 
considered to be clinically meaningful. For random-effects anal-
yses, the results are presented as the mean treatment effect with 
95% CIs, and the estimates of the tau2 and I2 statistics.
For dichotomous data, the number of events in the control 
and intervention groups was used to calculate the Mantel-
Haenszel risk ratios (RR). For the number needed to treat for 
an additional beneficial (NNTB) or harmful (NNTH) outcome, 
the recommendations given by Altman were followed.17 When 
we observed a treatment effect, we reported the NNTH or 
NNTB with 95% CIs. NNTB and NNTH are presented in the 
GRADE tables in the full Cochrane review.12 When possible, 
we performed analysis based on intention to treat (ITT). When 
information for an ITT analysis was not available, we used the 
results provided by the authors.
We undertook the following sensitivity analysis to investigate 
whether our conclusions were robust to methodological deci-
sions made by the review authors:
 ► Risk of bias (restricting analysis to blinded studies at low risk 
of selection bias).
rEsulTs
We identified 2133 records. After selection process, 37 studies 
met our inclusion criteria (figure 1).18–54
The characteristics of the included RCTs are presented in 
online supplementary material 1. The 37 trials included 6348 
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Figure 1 Study flow diagram. RCTs, randomised controlled trials.
Retrieved studies came from a wide range of inpatient and 
outpatient settings from different continents (North America, 
South America, Europe, Asia, Oceania and Africa). The trials 
recruited women aged 14 years and over with a diagnosis of 
PID according to the CDC criteria (pelvic or lower abdominal 
pain and one or more of the following clinical criteria: cervical 
motion tenderness, uterine tenderness or adnexal tenderness).2 
Studies varied in the degree of disease severity of participants.
Clinical cure in mild-moderate PID
Two trials compared azithromycin versus doxycycline in 
mild-moderate PID.20 21 There was no clear evidence of a differ-
ence between azithromycin and doxycycline regimens (RR 1.18, 
95% CI 0.89 to 1.55; 243 women, 2 studies; I2=72%; very 
low-quality evidence). Sensitivity analysis limited to the study 
at low risk of bias indicated that azithromycin was superior to 
doxycycline in achieving cure in mild-moderate PID (RR 1.35, 
95% CI 1.10 to 1.67; 133 women, 1 study; moderate-quality 
evidence).21
Three studies compared quinolones versus cephalosporins.22–24 
There was no clear evidence of a difference between the groups 
(RR 1.04, 95% CI 0.98 to 1.10; 459 women, 3 studies; I2=5%; 
low-quality evidence).
Clinical cure in mild-moderate PID was evaluated in five studies 
comparing nitroimidazoles versus no nitroimidazoles.19 25–28 
In all the studies the nitroimidazole used was metronidazole. 
There was no conclusive evidence of a difference in effective-
ness between metronidazole versus no use of metronidazole in 
mild-moderate PID (moderate-quality evidence; figure 2). Sensi-
tivity analysis restricted to the two studies at low risk of bias 
did not substantially change the main findings (RR 1.06, 95% 
CI 0.98 to 1.15; 1201 women, 2 studies; I2=32%; high-quality 
evidence).25 26
Clindamycin plus aminoglycoside versus quinolone in 
mild-moderate PID was evaluated in one study,18 which showed 
no difference in effectiveness between the regimens (RR 
0.88, 95% CI 0.69 to 1.13; 25 women, 1 study; I2=0%; very 
low-quality evidence).
Two studies compared clindamycin plus aminoglycoside 
versus cephalosporin in mild-moderate PID.29 30 There was no 
clear evidence of a difference between these regimens in the 
rates of cure for mild-moderate PID (RR 1.02, 95% CI 0.95 
to 1.09; 150 women, 2 studies; I2=0%; low-quality evidence).
Clinical cure in severe PID
One trial compared azithromycin versus doxycycline in severe 
PID.31 There was no clear evidence of a difference in the rates 
of cure between regimens using azithromycin or doxycycline 
to treat severe PID (RR 1.00, 95% CI 0.96 to 1.05; 309 
women, 1 study; low-quality evidence).
Two studies compared quinolones versus cephalosporins,32 33 
with no clear evidence of a difference in the rates of cure between 
regimens (RR 1.06, 95% CI 0.91 to 1.23; 313 women, 2 studies; 
I2=7%; low-quality evidence).
Eleven studies evaluated nitroimidazole in severe PID, and 
all studies used metronidazole.33–43 The difference in clinical 
cure rates between women treated with metronidazole and 
women not treated with it was small and was compatible with 
no effect (RR 0.96, 95% CI 0.92 to 1.01; 1383 women, 11 
trials; I2=3%; moderate-quality evidence; figure 3).
Two studies compared clindamycin plus aminoglycoside versus 
quinolone in severe PID.44 45 There was no clear evidence of a 
difference between these regimens in the rates of cure for severe 
PID (RR 1.02, 95% CI 0.87 to 1.19; 151 women, 2 studies; 
I2=0%; low-quality evidence).
The use of clindamycin plus aminoglycoside versus cepha-
losporin in severe PID was evaluated in 10 studies.29 30 46–53 
There was no clear evidence of a difference between these 
regimens in the rates of cure of severe PID (moderate-quality 
evidence; figure 4).
Adverse events
No clear evidence of a difference between regimens in anti-
biotic-related adverse events leading to discontinuation of 
therapy was observed for all comparisons.
Quality of the evidence
Most of the 37 included studies had unclear or high risk of 
bias in most domains, and only three were at low risk of bias 
in most domains.21 25 26 The overall quality of the evidence 
ranged from very low to high, the main limitations being 
serious risk of bias (due to poor reporting of study methods 
and lack of blinding), serious inconsistency and serious impre-
cision. The only high-quality evidence was for the sensitivity 
analysis regarding the use (or not) of nitroimidazole. There 
was moderate-quality evidence in the sensitivity analysis 
regarding the use of azithromycin in mild-moderate cases of 
PID, in comparisons between the use or not of nitroimidazole 
for curing mild-moderate or severe PID, and in comparisons 
between clindamycin plus aminoglycoside versus cephalospo-
rins for curing severe PID.
DIsCussIOn
Thirty-seven trials with 6348 women were included in the 
review. We found no clear evidence of a difference between 
any of the regimens studied in terms of effectiveness or safety. 
Within a sensitivity analysis of cases of mild-moderate PID for 
the comparison of macrolide (azithromycin) versus tetracy-
cline (doxycycline), we identified a single study at low risk of 
bias which provided moderate-quality evidence that azithro-
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Figure 2 Clinical cure in mild-moderate pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles. (+) low 
risk of bias, (−) high risk of bias, (?) unclear risk of bias. M-H, Mantel-Haenszel.
Figure 3 Clinical cure in severe pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles. (+) low risk of 
bias, (−) high risk of bias, (?) unclear risk of bias. M-H, Mantel-Haenszel.
Some guidelines have recommended the use of nitroimidazoles 
for PID,2 11 but we found no conclusive evidence of a differ-
ence in outcomes between the use or not of nitroimidazoles 
(metronidazole) in successfully treating PID. There was also 
no clear evidence of a difference in rates of adverse effects 
between the regimens.
The applicability of the evidence to the target population 
(women of reproductive age diagnosed with PID) was broad 
because the included trials were conducted in different clin-
ical settings and implemented varying diagnostic approaches. 
Additionally, the interventions analysed in the review are 
currently available and represent the most frequently used 
treatment regimens in current clinical practice. Given these 
factors, we consider that the evidence identified applies to a 
wide range of women with PID varying in disease severity, age, 
geographical location and diagnostic criteria, which provides 
external validity.
The trials included in this review cover a period of approx-
imately 30 years and several countries, with 7 out of 37 
studies being conducted after the year 2000. The searches for 
this review were last updated in July 2016 and new evidence 
may now be available. Considering the availability of addi-
tional studies, an update of this review is expected to take 
place in 2020. Little data are available on temporal variation 
in bacterial causes of PID because few countries systematically 
collect this information. Wide variations in the bacterial aeti-
ology of PID may occur in different geographical areas and 
these may affect the choice of treatment, but few trials were 
carried out in low-income/middle-income countries. Although 
we consider that the results of this review are generalisable to 
a wide range of geographical locations, our conclusions may 
not be generalisable to low-income/middle-income countries.
An important limitation of this systematic review was the 
potential for measurement bias introduced by using the inves-
tigators’ definitions of cure. This approach was necessary 
because of the wide variation in methods used and lack of a 
widely accepted objective outcome measure. The short-term 
follow-up in most studies prevented the identification of long-
term sequelae. In addition, the inaccuracy of clinical diag-
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Figure 4 Clinical cure in severe pelvic inflammatory disease in regimens containing clindamycin plus aminoglycoside versus cephalosporin. (+) low 
risk of bias, (−) high risk of bias, (?) unclear risk of bias. M-H, Mantel-Haenszel.
for clinical cure may have reduced the power of the analysis 
to detect a clinically relevant effect. Some studies identified 
PID and endometritis separately, but these were pooled for 
our analysis. Data were lacking for several of our secondary 
outcomes. None of the included studies reported data on 
fertility or laparoscopic evidence of PID resolution, and data 
were very scant on length of hospital stay.
Microbiological clearance of C. trachomatis and N. gonor-
rhoeae and clinical resolution of symptoms are the usual 
outcomes used in clinical practice and the current review 
reflects this.12 The utility of other biological markers (eg, 
mediators of inflammation, ‘new’ bacteria) is being explored, 
but their use as outcome measures is not yet established even 
in a research setting.55 56 Bacterial sequencing and 16S ribo-
somal RNA are also experimental, and their role in the diag-
nosis, or as prognostic markers, remains uncertain.
Increasing resistance in N. gonorrhoeae has implications 
for the treatment of gonococcal PID and strongly suggests 
that only parenteral third-generation cephalosporins should 
be used in this situation, but this accounts for a very small 
proportion of PID overall. Studies have demonstrated that 
women with PID are often coinfected with other micro-organ-
isms such as Mycoplasma genitalium, Trichomonas vaginalis, 
C. trachomatis and anaerobes. There is increasing recognition 
that M. genitalium is an important cause of PID, although 
only in a minority of women. However, few published studies 
(and no RCTs) have addressed this.11 57 The utility of azithro-
mycin as empirical treatment for M. genitalium is limited by 
increasing rates of resistance, and treatment with moxifloxacin 
is currently recommended for this group of patients.58 59 T. 
vaginalis has been associated with endometritis, but its role in 
PID remains uncertain.60 Bacterial vaginosis is not commonly 
associated with PID in prospective studies, although subgroups 
of women with bacterial vaginosis may be at higher risk, espe-
cially if coinfected with N. gonorrhoeae or C. trachomatis.61
Anaerobic bacteria are commonly identified in the fallopian 
tubes of women with PID,62 and most treatment guidelines 
include metronidazole to provide adequate microbiological 
cover. On meta-analysis we found that the addition of a 
nitroimidazole (metronidazole) did not improve short-term 
clinical outcomes of either mild-to-moderate or severe PID, 
which suggests that the other components of treatment regi-
mens may be adequate. This is potentially important since 
nitroimidazoles commonly cause gastrointestinal side effects 
and may limit adherence to therapy. Nevertheless, some 
studies used antimicrobials with anaerobic cover, such as 
amoxicillin+clavulanate.28 The only study, in this system-
atic review, that did not use any antibiotic with anaerobic 
coverage found that women who did not receive nitroimida-
zole were more likely to experience clinical cure than those 
who received nitroimidazole.28 Of note, the study conducted 
by Burchell et al28 had a small sample size and lacked infor-
mation to assess risk of bias. We were not able to assess long-
term outcomes such as infertility or chronic pelvic pain, and 
it remains uncertain whether the use of nitroimidazoles 
affects the risk of these sequelae.
One previous meta-analysis, published in 1993, formed 
the basis for the CDC guidelines.63 The authors reported 
pooled clinical cure rates ranging from 75% to 94%, which 
is similar to our updated review with overall rate of cure of 
81%. The uncertainty in using nitroimidazoles when treating 
PID is reflected in the current guidelines. The 2015 US CDC 
PID guideline2 advises that metronidazole be considered to 
provide additional anaerobic cover but does not mandate 
its use. The 2017 European IUSTI PID guideline11 and the 
2018 BASHH PID guideline64 recommend the use of metro-
nidazole but advise that it can be discontinued in those with 
mild to moderate symptoms if they develop drug-related 
side effects. Our analysis does not support the routine use 
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moderate PID and can be used to inform future guideline 
revisions.
Differences between the Cochrane review and the current 
review
The current review is an abridged version of a Cochrane 
systematic review and presents the main findings and an 
enhanced discussion section.12 The secondary outcomes 
presented in the Cochrane review were microbiological 
clearance of C. trachomatis, microbiological clearance of 
N. gonorrhoeae, laparoscopic evidence of resolution of PID 
based on physician opinion, length of stay (for inpatient 
care) and rate of fertility. The results were similar for studies 
that reported microbiological clearance of C. trachomatis or 
N. gonorrhoeae, with clearance occurring in over 90% of 
women irrespective of regimen used. Length of stay varied 
across the studies, ranging from 3 days to 18 days. No data 
were found for laparoscopic evidence of resolution of PID 
and for rate of fertility.
COnClusIOn
We found no evidence that one regimen is more effective or 
safer than any other for the treatment of PID, and there is no 
clear evidence that the addition of nitroimidazoles is benefi-
cial. Adherence to clinical treatment for PID is an important 
issue that should be considered when choosing a treatment 
regimen. Moderate-quality evidence from a single study at 
low risk of bias suggests that a macrolide (azithromycin) may 
be more effective than a tetracycline (doxycycline) for curing 
mild-moderate PID. There remains a need for high-quality 
RCTs to assess treatments for women with PID, particularly 
comparing regimens with or without the addition of nitroim-
idazoles and comparing azithromycin (eg, 1 g once a week for 
2 weeks) with doxycycline. The lack of a consistent outcome 
measure to assess response to therapy is a major limitation, 
and there is a clear need for core outcome measures to be 
developed.
Key messages
 ► There is no clear evidence that any one of the currently 
recommended treatment regimens for pelvic inflammatory 
disease (PID) is superior to another.
 ► There is no evidence of improved efficacy when 
metronidazole is included within a treatment regimen, 
although this is currently recommended in some guidelines.
 ► There is a need for better understanding of the role of 
azithromycin in the treatment of PID, given uncertainty about 
its efficacy compared with doxycycline and concerns about 
inducing antimicrobial resistance.
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